Bietti crystalline dystrophy (BCD) is a rare, inherited eye disorder that progressively impairs vision. Named after the Italian ophthalmologist Dr. G. B. Bietti who first described it in the 1930s, this condition is characterized by the formation of crystal-like deposits in the retina and other parts of the eye. Despite its rarity, understanding BCD is crucial for both patients and healthcare professionals to facilitate early detection, management, and potential treatment strategies. In this comprehensive guide, we delve into the symptoms, causes, diagnosis, and available treatments for Bietti crystalline dystrophy.

The symptoms of Bietti crystalline dystrophy typically manifest in early to mid-adulthood and progressively worsen over time. Individuals affected by BCD may experience:

• Decreased Visual Acuity: The decrease in visual acuity in BCD is typically gradual but progressive. It often starts with difficulty focusing on fine details or objects at a distance. Central vision loss occurs as the disease advances, affecting tasks such as reading, recognizing faces, or driving. Patients may notice that their vision becomes increasingly blurry or distorted over time.
• Night Blindness: Nocturnal vision impairment, or night blindness, is a common symptom of BCD. This occurs due to the degeneration of the retina’s rod photoreceptor cells, which are responsible for low-light vision. Individuals may find it challenging to navigate dimly lit environments or may take longer to adjust to changes in lighting conditions.
• Peripheral Vision Loss: Progressive loss of peripheral vision, also known as peripheral field constriction or tunnel vision, is another hallmark of BCD. This narrowing of the visual field can significantly impact spatial awareness and peripheral awareness, making activities like walking in crowded spaces or driving more challenging.
• Photophobia: Increased sensitivity to light can manifest as discomfort, pain, or even avoidance of brightly lit environments. Photophobia may worsen as the disease progresses, leading individuals to seek shaded areas or wear sunglasses indoors and outdoors.
• Eye Discomfort: Some patients with BCD may experience sensations of dryness, grittiness, or foreign body sensation in the eyes. This discomfort may be due to corneal abnormalities or secondary dry eye syndrome, which can occur as a result of decreased tear production or altered tear film composition.

Bietti crystalline dystrophy is primarily an autosomal recessive genetic disorder caused by mutations in the CYP4V2 gene located on chromosome 4q35. The CYP4V2 gene encodes an enzyme called cytochrome P450 family 4 subfamily V member 2, which plays a crucial role in lipid metabolism, particularly in the breakdown of fatty acids and cholesterol in cells. Mutations in the CYP4V2 gene lead to a dysfunctional enzyme, disrupting lipid metabolism and causing the accumulation of lipid deposits within retinal cells. These lipid deposits, including cholesterol and other lipids, form characteristic crystal-like structures known as Bietti crystals. The exact mechanisms by which these crystals contribute to retinal degeneration are still under investigation, but they are thought to disrupt cellular function, induce inflammation, and ultimately lead to photoreceptor cell death and retinal degeneration.

In addition to the mentioned tests, other diagnostic modalities may be employed to evaluate the extent of retinal degeneration and monitor disease progression:

• Optical Coherence Tomography (OCT): This non-invasive imaging technique provides high-resolution cross-sectional images of the retina, allowing for detailed visualization of retinal layers, thickness measurements, and the identification of structural abnormalities such as retinal thinning or fluid accumulation.
• Visual Field Testing: Perimetry, or visual field testing, assesses the full horizontal and vertical range of a patient’s vision. It helps detect peripheral vision loss, which is a characteristic feature of BCD. Progressive constriction of the visual field may be observed over time.
• Multifocal Electroretinography (mfERG): Similar to traditional ERG, mfERG measures the electrical responses of different areas of the retina to light stimulation. It provides detailed information about regional retinal function, which can aid in the early detection and monitoring of BCD-related changes.

Currently, there is no cure for Bietti crystalline dystrophy. Treatment aims to manage symptoms, slow disease progression, and preserve remaining vision. Strategies may include:

• Regular Monitoring: Close monitoring by an ophthalmologist or retina specialist is essential for assessing disease progression, managing complications, and adjusting treatment strategies as needed. Regular eye examinations, including visual acuity testing, fundus photography, and OCT imaging, help track changes in visual function and retinal structure over time.
• Low-Vision Rehabilitation: Low-vision aids and rehabilitation services can help individuals with BCD optimize their remaining vision and adapt to visual impairment. These may include magnification devices, such as handheld magnifiers, electronic magnifiers, or video magnification systems, as well as orientation and mobility training to improve independent navigation and daily living skills.
• Intravitreal Injections: In cases where BCD is complicated by choroidal neovascularization (CNV), a complication characterized by abnormal blood vessel growth beneath the retina, intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) medications may be recommended. Anti-VEGF therapy helps inhibit the growth of abnormal blood vessels, reduce fluid leakage, and improve visual outcomes in patients with CNV-associated BCD.
• Gene Therapy and Emerging Therapies: Several research initiatives are exploring gene therapy as a potential treatment for inherited retinal diseases, including BCD. Gene therapy aims to introduce functional copies of the defective gene into retinal cells, restoring normal gene expression and preventing further retinal degeneration. Clinical trials investigating gene-based interventions, as well as other emerging therapeutic approaches such as stem cell therapy and small molecule-based therapies, offer hope for future treatment options for BCD and other rare genetic eye disorders. These innovative strategies hold promise for slowing or halting disease progression, preserving vision, and improving the quality of life for individuals affected by BCD.

Bietti crystalline dystrophy represents a complex and challenging condition characterized by progressive retinal degeneration and vision loss. While there is currently no cure for BCD, ongoing research efforts are focused on understanding its underlying genetic mechanisms and developing novel treatment approaches. Early diagnosis, regular monitoring, and access to comprehensive eye care services and supportive resources are essential for managing symptoms, optimizing visual function, and enhancing the quality of life for individuals living with BCD. By raising awareness, fostering collaboration among researchers and healthcare providers, and advocating for continued investment in vision research, we can work towards improving diagnosis, treatment, and outcomes for individuals affected by Bietti crystalline dystrophy and other inherited retinal diseases.

World Eye Care Foundation’s eyecare.live brings you the latest information from various industry sources and experts in eye health and vision care. Please consult with your eye care provider for more general information and specific eye conditions. We do not provide any medical advice, suggestions or recommendations in any health conditions.